Natural hormone therapy for menopause

被引:10
作者
Mahmud, Khalid [1 ]
机构
[1] Innovat Direct Hlth, Edina, MN 55435 USA
关键词
HRT; hormonal therapy; menopause; bio-identical; women's health; ESTROGEN PLUS PROGESTIN; BREAST-CANCER CELLS; RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; MEDROXYPROGESTERONE ACETATE; REPLACEMENT THERAPY; RISK; SERUM; PREVENTION; APOPTOSIS;
D O I
10.3109/09513590903184134
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Menopausal women are deficient in estrogen, progesterone, and frequently in testosterone and DHEA. Hormone replacement therapy (HRT) in the United States has generally consisted of one or two agents, typically equine estrogen and medroxyprogesterone, with increased risk of heart attack, stroke, dementia, and breast cancer [WHI trials]. Bio-identical hormones [chemically endogenous hormones] have gained popularity and can be mixed according to physician's orders by compounding pharmacists in the United States. However, there is little published information about the use of such hormones. This paper reports a 12 plus months follow up on 189 patients who were administered natural estrogen plus progesterone with or without DHEA or testosterone according to a rationalized protocol described later. Ninety-seven percent of the patients experienced varying degrees of symptom control, whereas three had minimal or questionable benefit. Mental symptoms experienced upon presentation improved in 90% of the patients. Sixty percent of the patients, who had gained weight during menopause, lost an average of 14.8 lbs [SD 11.98 lbs]. Complications described with traditional HRT did not develop in this group of patients. These findings point out a need for larger controlled trials of similar protocols in the management of menopause.
引用
收藏
页码:81 / 85
页数:5
相关论文
共 27 条
[1]   Influence of estrogen plus progestin on breast, cancer and mammography in healthy postmenopausal women - The Women's Health Initiative Randomized trial [J].
Chlebowski, RT ;
Hendrix, SL ;
Langer, RD ;
Stefanick, ML ;
Gass, M ;
Lane, D ;
Rodabough, RJ ;
Gilligan, MA ;
Cyr, MG ;
Thomson, CA ;
Khandekar, J ;
Petrovitch, H ;
McTiernan, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (24) :3243-3253
[2]   17-BETA-ESTRADIOL ATTENUATES ACETYLCHOLINE-INDUCED CORONARY ARTERIAL CONSTRICTION IN WOMEN BUT NOT MEN WITH CORONARY HEART-DISEASE [J].
COLLINS, P ;
ROSANO, GMC ;
SARREL, PM ;
ULRICH, L ;
ADAMOPOULOS, S ;
BEALE, CM ;
MCNEILL, JG ;
POOLEWILSON, PA .
CIRCULATION, 1995, 92 (01) :24-30
[3]  
Formby B, 1998, ANN CLIN LAB SCI, V28, P360
[4]   Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: Inhibition of cell growth and induction of apoptosis [J].
Formby, B ;
Wiley, TS .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 1999, 202 (1-2) :53-61
[5]   Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort [J].
Fournier, A ;
Berrino, F ;
Riboli, E ;
Avenel, V ;
Clavel-Chapelon, F .
INTERNATIONAL JOURNAL OF CANCER, 2005, 114 (03) :448-454
[6]   Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone [J].
Hermsmeyer, RK ;
Mishra, RG ;
Pavcnik, D ;
Uchida, B ;
Axthelm, MK ;
Stanczyk, FZ ;
Burry, KA ;
Illingworth, DR ;
Kaski, JC ;
Nordt, FJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (05) :955-961
[7]  
Jefcoate C R, 2000, J Natl Cancer Inst Monogr, P95
[8]  
LEMON HM, 1973, LANCET, V1, P546
[9]  
LEMON HM, 1980, ACTA ENDOCRINOL-COP, V94, P17
[10]   Hormone therapy and risk of myocardial infarction: a national register study [J].
Lokkegaard, Ellen ;
Andreasen, Anne Helms ;
Jacobsen, Rikke Kart ;
Nielsen, Lars Hougaard ;
Agger, Carsten ;
Lidegaard, Ojvind .
EUROPEAN HEART JOURNAL, 2008, 29 (21) :2660-2668